Stock Worth Mentioning: Could Rockwell Medical Inc Crash Even More? The Stock Had Another Big Decline Today

Stock Worth Mentioning: Could Rockwell Medical Inc Crash Even More? The Stock Had Another Big Decline Today

The stock of Rockwell Medical Inc (NASDAQ:RMTI) is a huge mover today! About 2.82M shares traded hands or 867.58% up from the average. Rockwell Medical Inc (NASDAQ:RMTI) has declined 25.33% since April 6, 2016 and is downtrending. It has underperformed by 27.29% the S&P500.
The move comes after 5 months negative chart setup for the $216.55M company. It was reported on Nov, 8 by Barchart.com. We have $3.66 PT which if reached, will make NASDAQ:RMTI worth $28.15 million less.

Analysts await Rockwell Medical Inc (NASDAQ:RMTI) to report earnings on November, 14. They expect $-0.10 earnings per share, down 100.00% or $0.05 from last year’s $-0.05 per share. After $-0.11 actual earnings per share reported by Rockwell Medical Inc for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

According to Zacks Investment Research, “Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly.”

Insitutional Activity: The institutional sentiment decreased to 0.9 in 2016 Q2. Its down 0.26, from 1.16 in 2016Q1. The ratio turned negative, as 11 funds sold all Rockwell Medical Inc shares owned while 28 reduced positions. 9 funds bought stakes while 26 increased positions. They now own 10.76 million shares or 10.05% less from 11.96 million shares in 2016Q1.
Bancorp Of New York Mellon reported 244,405 shares or 0% of all its holdings. The Missouri-based Cutter Brokerage has invested 0.09% in Rockwell Medical Inc (NASDAQ:RMTI). Moreover, Bnp Paribas Arbitrage has 0% invested in Rockwell Medical Inc (NASDAQ:RMTI) for 1,862 shares. Palo Cap, a California-based fund reported 49,166 shares. Rhumbline Advisers last reported 0% of its portfolio in the stock. Utd Services Automobile Association holds 0% of its portfolio in Rockwell Medical Inc (NASDAQ:RMTI) for 46,910 shares. Huntington Commercial Bank has invested 0% of its portfolio in Rockwell Medical Inc (NASDAQ:RMTI). Blackrock Grp owns 27,970 shares or 0% of their US portfolio. Manufacturers Life The has 33,780 shares for 0% of their US portfolio. Swiss National Bank & Trust has 93,100 shares for 0% of their US portfolio. Ubs Asset Mngmt Americas reported 32,400 shares or 0% of all its holdings. Synovus Financial last reported 0% of its portfolio in the stock. Creative Planning holds 53,279 shares or 0% of its portfolio. Provident Inv has 0.04% invested in the company for 27,108 shares. The Ohio-based Johnson Inv Counsel Incorporated has invested 0.01% in Rockwell Medical Inc (NASDAQ:RMTI).

Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 4 selling transactions for $105,555 net activity. 8,075 Rockwell Medical Inc (NASDAQ:RMTI) shares with value of $54,977 were sold by HOLT KENNETH L.

More notable recent Rockwell Medical Inc (NASDAQ:RMTI) news were published by: Fool.com which released: “3 Ways Rockwell Medical Inc. Could Turn Things Around” on October 07, 2016, also Fool.com with their article: “3 Predictions for Rockwell Medical Inc. in 2016” published on December 10, 2015, Fool.com published: “Will Rockwell Medical Inc. Sink or Swim?” on April 06, 2016. More interesting news about Rockwell Medical Inc (NASDAQ:RMTI) were released by: Fool.com and their article: “Why Rockwell Medical, Inc. Shares Are Crashing Today” published on March 01, 2016 as well as Fool.com‘s news article titled: “Rockwell Medical Stock Upgraded: What You Need to Know” with publication date: August 19, 2016.

RMTI Company Profile

Rockwell Medical, Inc. (Rockwell), incorporated on October 25, 1996, is a biopharmaceutical firm targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with services and products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Firm operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s lead branded drug, Triferic is indicated for iron maintenance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment